Patrick Walsh Sells 3,973 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Patrick Walsh sold 3,973 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $80.75, for a total transaction of $320,819.75. Following the completion of the transaction, the director directly owned 48,432 shares of the company’s stock, valued at approximately $3,910,884. This represents a 7.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

ANI Pharmaceuticals Trading Down 1.6%

Shares of NASDAQ ANIP opened at $79.58 on Friday. ANI Pharmaceuticals, Inc. has a 1-year low of $56.71 and a 1-year high of $99.50. The company has a market cap of $1.78 billion, a PE ratio of 20.15 and a beta of 0.46. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. The company has a 50-day moving average of $77.26 and a two-hundred day moving average of $80.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same period in the previous year, the firm posted $1.70 earnings per share. The company’s revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ANIP shares. Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals News Roundup

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals posted a strong first quarter, with EPS of $2.05 beating estimates of $1.28 and revenue of $237.46 million topping expectations, while management also guided FY2026 EPS to $9.19-$9.69, reinforcing the company’s growth story.
• Positive Sentiment: Analyst sentiment remains favorable, with recent upgrades and a consensus “Moderate Buy” rating plus an average price target above the current trading range, which can support longer-term confidence in ANIP.
• Neutral Sentiment: ANI Pharmaceuticals updated its investor presentation and highlighted non-GAAP metrics, a routine corporate communication that does not appear to materially change the near-term outlook. ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
• Negative Sentiment: CEO Nikhil Lalwani sold 55,000 shares, and other executives and directors also trimmed holdings, including Patrick D. Walsh, Meredith Cook, Ori Gutwerg, and Thomas Andrew Rowland; heavy insider selling can weigh on sentiment even when some trades are pre-planned.
• Negative Sentiment: A separate filing reported that Global Alpha sold 229,000 ANIP shares worth about $17.9 million, adding to concerns that a large investor may be reducing exposure. Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ANIP. KBC Group NV acquired a new position in ANI Pharmaceuticals during the first quarter valued at approximately $28,000. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the first quarter valued at approximately $28,000. Hantz Financial Services Inc. grew its holdings in ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares during the period. Kemnay Advisory Services Inc. acquired a new position in ANI Pharmaceuticals during the fourth quarter valued at approximately $48,000. Finally, State of Wyoming acquired a new position in ANI Pharmaceuticals during the second quarter valued at approximately $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.